Under the terms of the agreement, Mariel acquired the rights to over 450 issued and pending patents, Stryker’s BMP-7-related clinical and research data, and the associated biologic materials.
Stryker will have a right of first negotiation for commercial rights in the area of osteoarthritis. Financial terms of the transaction were not disclosed.
Human recombinant BMP-7 has previously been used in reconstructive bone applications in over 40,000 patients.
Previous Phase I and Phase IIa trials have been completed in osteoarthritis. Mariel intends to pursue a Phase IIb/III clinical trial for osteoarthritis (OA) and Phase I trials for chronic kidney disease (CKD) and Alport’s disease, a genetic kidney fibrosis disease.
Mariel is a clinical stage biopharmaceutical company focused on the clinical application of Bone Morphogenetic Protein-7 (BMP-7) in osteoarthritis (OA), chronic kidney disease (CKD), and Alport’s Syndrome.